FDA approves Watson's generic version of Alzheimer's treatment

12/17/2008

CORONA, Calif. The Food and Drug Administration has approved Watson Pharmaceuticals' generic version of Razadyne ER capsules, Watson announced on Tuesday, Dec. 16.

The extended-release capsules, known generically as galantamine hydrobromide, are used for treating Alzheimer's disease. Watson will market them in 8 mg, 16 mg and 24 mg strengths.

The branded version of the drug, made by Johnson & Johnson, had sales of $112 million for the 12 months ending in September, according to IMS Health data.

X
This ad will auto-close in 10 seconds